Your browser is no longer supported. Please, upgrade your browser.
Settings
INO Inovio Pharmaceuticals, Inc. daily Stock Chart
INO [NASD]
Inovio Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.70 Insider Own1.40% Shs Outstand167.52M Perf Week-1.91%
Market Cap2.37B Forward P/E25.40 EPS next Y0.61 Insider Trans-9.24% Shs Float164.19M Perf Month21.79%
Income-222.00M PEG- EPS next Q-0.19 Inst Own34.20% Short Float31.56% Perf Quarter-50.82%
Sales2.70M P/S878.99 EPS this Y-15.40% Inst Trans40.48% Short Ratio1.67 Perf Half Y114.97%
Book/sh1.20 P/B12.81 EPS next Y140.80% ROA-82.40% Target Price19.00 Perf Year614.88%
Cash/sh2.41 P/C6.39 EPS next 5Y0.00% ROE-217.80% 52W Range1.91 - 33.79 Perf YTD365.76%
Dividend- P/FCF- EPS past 5Y-14.60% ROI-137.90% 52W High-50.07% Beta0.86
Dividend %- Quick Ratio10.10 Sales past 5Y-17.00% Gross Margin- 52W Low780.94% ATR1.85
Employees190 Current Ratio10.10 Sales Q/Q200.00% Oper. Margin- RSI (14)56.94 Volatility14.11% 13.79%
OptionableYes Debt/Eq0.43 EPS Q/Q-175.70% Profit Margin- Rel Volume0.61 Prev Close15.37
ShortableYes LT Debt/Eq0.43 EarningsAug 10 AMC Payout- Avg Volume31.07M Price16.87
Recom2.90 SMA2030.19% SMA501.94% SMA20048.77% Volume8,557,901 Change9.76%
Jul-01-20Downgrade ROTH Capital Neutral → Sell $11
Jul-01-20Downgrade Maxim Group Buy → Hold
Jun-29-20Downgrade H.C. Wainwright Buy → Neutral
Jun-26-20Downgrade Stifel Buy → Hold $19 → $24
May-21-20Initiated The Benchmark Company Buy $28
Apr-30-20Downgrade ROTH Capital Buy → Neutral $13
Mar-13-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-13-20Downgrade Piper Sandler Overweight → Neutral
Dec-19-19Initiated ROTH Capital Buy $13
Feb-15-18Reiterated Maxim Group Buy $12 → $8
Oct-18-17Initiated RBC Capital Mkts Outperform $11
Sep-06-17Initiated Citigroup Buy $10
Jun-08-17Upgrade Piper Jaffray Neutral → Overweight
May-24-17Reiterated Maxim Group Buy $10 → $12
Mar-16-17Upgrade Maxim Group Hold → Buy $10
Mar-16-17Downgrade Piper Jaffray Overweight → Neutral
Nov-07-16Initiated Aegis Capital Buy
Aug-09-16Downgrade Maxim Group Buy → Hold
Mar-15-16Reiterated Stifel Buy $19 → $13
Jan-05-16Reiterated Maxim Group Buy $23 → $14
Sep-25-20 10:39AM  
09:24AM  
Sep-23-20 11:50AM  
Sep-22-20 06:04AM  
Sep-21-20 03:35PM  
Sep-18-20 02:50PM  
12:47PM  
11:49AM  
Sep-17-20 05:35PM  
10:36AM  
Sep-16-20 04:20PM  
02:04PM  
11:32AM  
10:29AM  
Sep-15-20 06:04PM  
11:31AM  
06:11AM  
Sep-14-20 12:25PM  
06:45AM  
Sep-10-20 03:10PM  
10:02AM  
Sep-09-20 06:20PM  
11:43AM  
08:03AM  
07:08AM  
Sep-08-20 04:25PM  
03:29PM  
09:46AM  
09:36AM  
08:27AM  
08:00AM  
Sep-04-20 10:53AM  
Sep-03-20 03:29PM  
07:50AM  
06:10AM  
Sep-02-20 05:23PM  
01:34PM  
06:37AM  
Sep-01-20 03:39PM  
08:00AM  
Aug-28-20 01:51PM  
12:03PM  
07:59AM  
Aug-27-20 10:32AM  
06:08AM  
Aug-26-20 07:34AM  
Aug-24-20 11:14AM  
Aug-23-20 06:12AM  
Aug-21-20 01:46PM  
11:31AM  
Aug-19-20 06:09AM  
Aug-16-20 09:10AM  
07:07AM  
Aug-15-20 08:14AM  
07:02AM  
Aug-14-20 10:55AM  
Aug-13-20 06:42PM  
12:42PM  
08:33AM  
07:32AM  
05:04AM  
Aug-12-20 12:07PM  
11:30AM  
Aug-11-20 04:47PM  
04:42PM  
03:17PM  
01:21PM  
11:27AM  
08:58AM  
08:20AM  
07:35AM  
04:49AM  
02:30AM  
12:00AM  
Aug-10-20 10:52PM  
05:17PM  
04:05PM  
Aug-07-20 11:01AM  
Aug-05-20 06:41AM  
Aug-04-20 06:46AM  
Aug-02-20 11:00AM  
Jul-31-20 10:54AM  
08:48AM  
06:00AM  
Jul-30-20 11:25AM  
08:34AM  
08:00AM  
Jul-29-20 10:33AM  
09:13AM  
07:30AM  
Jul-28-20 07:02AM  
05:51AM  
Jul-27-20 08:00AM  
Jul-26-20 02:33PM  
Jul-25-20 08:08AM  
01:21AM  
Jul-24-20 12:16PM  
08:49AM  
06:46AM  
Jul-23-20 09:00AM  
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Humeau LaurentChief Scientific OfficerAug 10Sale19.0619,467371,00443,966Aug 12 06:59 PM
Kim Jong JosephChief Executive OfficerJul 30Sale21.13100,0002,113,4501,188,313Jul 31 07:12 PM
KIES PETERCFOJul 15Option Exercise2.4035,00084,000154,290Jul 17 07:00 PM
KIES PETERCFOJul 15Sale24.9535,000873,208119,290Jul 17 07:00 PM
KIES PETERCFOJun 30Sale26.5035,000927,500119,290Jul 02 09:05 PM
Humeau LaurentChief Scientific OfficerJun 22Sale14.7019,467286,16563,433Jun 24 04:56 PM
BENITO SIMON XDirectorMay 20Option Exercise4.608,75040,25060,400May 20 05:37 PM
BENITO SIMON XDirectorMay 20Sale15.958,750139,59451,650May 20 05:37 PM
Weiner David B.DirectorMay 11Sale11.842,40428,463827,219May 12 04:26 PM
Weiner David B.DirectorMar 12Sale11.143,50038,990821,610Mar 12 04:40 PM
Weiner David B.DirectorMar 10Sale9.323,50032,620825,110Mar 12 04:40 PM
Weiner David B.DirectorMar 09Sale18.003,50063,000816,944Mar 09 04:20 PM
Kim Jong JosephChief Executive OfficerJan 13Buy3.1122,50069,9751,100,707Jan 13 12:10 PM